Mechanisms to influence other stakeholders identify the ideal

mechanisms that can or are use to influence other stake holders in a

positive and negative way about the brand

Meetings: the most common ways to communicate. They can vary from only 1
person to thousands based on message and audience appropriate. It is up to
you to maximize every minute of the time spent to have dialogue.

Email:This strategy is one way communication and utilizes emailed updates,

hard copy brochures, posters, newsletters mailed or emailed.

Calls: he dialogue can take place though its dependant on voice intonation and
clarity of the verbal message. They only require cost of phone call and there
are many paid and free services

D Potential risk the brand may face. All brands that have a global
presence have many types of risk identify the most common risk the brand
faces today

insufficient production capacity

There is a risk of failure or breakdown in any of the companys vital production facilities, which, in
addition to the potential physical damage or loss of life, could affect the supply of products. Fireprevention design, alarms and fire instructions, annual inspections, back-up fa -cilities and minimum
safety inventories help mitigate this risk. To spread risks and optimize costs and logistics, Novo
Nordisk is building up a global sourcing programme, with major investments in expanding
production capacity in for example the US, Brazil and China. This also entails contracting with local
suppliers. To mitigate risks of non-compliance with Novo Nordisks environmental and social
standards, specific requirements are made and audits conducted.

Legal issues
Vigilant compliance with regulations and legislation is expected of any pharmaceutical company.
Patient safety must never be comprom -ised. Any questioning of this entails a violation of Novo
Nordisks values as well as major financial and reputational risks. A related risk is product liability
claims. The most significant risk for Novo Nordisk in this context is in relation to HRT products,
where Novo Nordisk Inc., together with the majority of hormone therapy product manufacturers in
the US, is a defendant in product liability lawsuits related to hormone therapy products. There is a
risk of an unfavourable outcome for Novo Nordisk in the HRT litigation. Also, Menarini, Italy, has
sued Novo Nordisk for damages relating to distribution on the Italian market. At this point in time,
Novo Nordisk does not expect the pending claim to have a material impact on Novo Nordisks
financial outlook

Biosimilar competition
The market for therapeutic proteins is becoming more attractive to bio similar producers as more
lenient regulatory rules in Europe and in the US give bio similar companies an easier pathway to
these markets, when branded products go off-patent. Low-priced bio similar human insulin from
producers in China, India and Poland is one example. Novo Nordisks exposure to this risk factor is
diminishing due to the increasing use of patented modern insulins in Novo Nordisks portfolio.

Ethical marketing practices

In a competitive environment with increasing public scrutiny and regulation, the risk of legal action
related to marketing practices is ever present. A Business Ethics Policy and related audits as well
as other initiatives to reinforce the Novo Nordisk Way of Management paired with close monitoring
of performance and enhanced reporting requirements help to mitigate such risks.

What tools did you identify the use to promote ists corporate culture

Business ethics
Each day, Novo Nordisk employees bring ethical standards to work. Doing business
globally entails many challenges, particularly when working in diverse cultures where
concepts of appropriate business conduct can vary widely. Making the right choices
becomes more complex and more important with the pressures of a competitive
business environment.

Ethical business conduct is about values and integrity as well as compliance and risk
mitigation. Taking a proactive approach also presents opportunities such as enhanced
trust in the company and improved relationships with key stakeholders.

Training
The Business Ethics Compliance Office supports the development and implementation of
effective education and training programmes related to compliance. Training activities for
employees are split between corporate certification of procedures for all employees in
scope, e-learning courses targeting a broad audience, and tailored face-to-face training
focusing on in-depth and interactive dialogue with key employee groups.

Values

We create value by having a patient centred business approach.

We set ambitious goals and strive for excellence.

We are accountable for our financial, environmental and social

performance.

We provide innovation to the benefit of our stakeholders.

We build and maintain good relations with our key stakeholders.

We treat everyone with respect.